Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Perspective Therapeutics (CATX) Invested Capital (2016 - 2025)

Perspective Therapeutics' Invested Capital history spans 15 years, with the latest figure at $242.2 million for Q3 2025.

  • For Q3 2025, Invested Capital fell 26.26% year-over-year to $242.2 million; the TTM value through Sep 2025 reached $242.2 million, down 26.26%, while the annual FY2024 figure was $290.7 million, 286.63% up from the prior year.
  • Invested Capital for Q3 2025 was $242.2 million at Perspective Therapeutics, down from $265.7 million in the prior quarter.
  • Across five years, Invested Capital topped out at $341.0 million in Q2 2024 and bottomed at $54.6 million in Q4 2022.
  • The 5-year median for Invested Capital is $98.8 million (2023), against an average of $151.9 million.
  • The largest annual shift saw Invested Capital soared 1190.66% in 2021 before it fell 26.26% in 2025.
  • A 5-year view of Invested Capital shows it stood at $64.4 million in 2021, then dropped by 15.14% to $54.6 million in 2022, then soared by 37.58% to $75.2 million in 2023, then skyrocketed by 286.63% to $290.7 million in 2024, then dropped by 16.67% to $242.2 million in 2025.
  • Per Business Quant, the three most recent readings for CATX's Invested Capital are $242.2 million (Q3 2025), $265.7 million (Q2 2025), and $284.6 million (Q1 2025).